Invention in the REGENERATIVE MEDICINE is what we do every day, benefits of patients is our final goal
| Cata #: | Name of Product: | Price: |
| VRP-3105 | Recombinant SARS-CoV-2 Nucleocapsid (N) Protein | $100 |
| Product Name: | Recombinant SARS-CoV-2 Nucleocapsid (N) Protein |
| Catalog #: | VRP-3105 |
| Manufacture: | LD Biopharma, Inc. |
| Intruduction: | The beginning of 2020 has seen the emergence of COVID-19 outbreak caused by a novel Coronavirus: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Viral Nucleocapsid (N) protein (419aa) protein has been successfully used as immunogenic reagent for immunological / serological studies. This recombinant Nucleocapsid gene was codon optimized using gene synthesis technology, and was expressed in E. coli as inclusion bodies. The final product was refolded using our unique “temperature shift inclusion body refolding” technology and chromatographically purified. |
| Gene Symbol: | Nucleocapsid ( N ) |
| Accession Number: | MN908947 |
| Species: | SARS-Cov-2 |
| Package Size: | 50 µg / Vial |
| Composition: | 1.0 mg/ml, sterile-filtered, in 50 mM HEPES Buffer: pH 7.5, with proprietary formulation of NaCl, KCl, Sucrose, DTT and others. |
| Storage: | In Liquid. Keep at -20°C for long term storage. Product is stable at 4 °C for at least two weeks. |
| Key Reference: | Wu, F. et al., 2020: A new coronavirus associated with human respiratory disease in China. Nature 579(7798): 265-269. Ahmed, S. et al., 2020: Targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV Immunological Studies. Viruses, 12:254. doi:10.3390/v12030254 Wendong Li, et al., 2020: Bats are natural reservoirs of SARA-Like coronaviruese, Science. Vol : 310; 20 Oct. 676-678. (2005) |
| Applications: | Antigen for immunization as well as various immunochemical assays including ELISA and immunohistochemistry (IHC). |
| Quality Control: | Purity: > 94% by SDS-PAGE. |
| Recombinant Protein Sequence: | MSDNGPQNQRNAPRITFGGPSDSTGSNQNGERSGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQGVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALNTPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSRGTSPARMAGNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGPEQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKDQVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA |